Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IBSP Biologics Sequence Review Report 2026: Integrin-binding sialoprotein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IBSP Biologics Sequence Review Report 2026: Integrin-binding sialoprotein Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IBSP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
DSCAM Biologics Sequence Review Report 2026: Cell adhesion molecule DSCAM Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
DSCAM Biologics Sequence Review Report 2026: Cell adhesion molecule DSCAM Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DSCAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
HDGF Biologics Sequence Review Report 2026: Hepatoma-derived growth factor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
HDGF Biologics Sequence Review Report 2026: Hepatoma-derived growth factor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of HDGF protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BCAM Biologics Sequence Review Report 2026: Basal cell adhesion molecule Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BCAM Biologics Sequence Review Report 2026: Basal cell adhesion molecule Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of BCAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CHL1 Biologics Sequence Review Report 2026: Neural cell adhesion molecule L1-like protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CHL1 Biologics Sequence Review Report 2026: Neural cell adhesion molecule L1-like protein Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CHL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SSC5D Biologics Sequence Review Report 2026: Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SSC5D Biologics Sequence Review Report 2026: Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of SSC5D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MEGF11 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MEGF11 Biologics Sequence Review Report 2026: Multiple epidermal growth factor-like domains protein 11 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of MEGF11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KLK3 Biologics Sequence Review Report 2026: Prostate-specific antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KLK3 Biologics Sequence Review Report 2026: Prostate-specific antigen Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of KLK3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNW1 Biologics Sequence Review Report 2026: Interferon omega-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNW1 Biologics Sequence Review Report 2026: Interferon omega-1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNW1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNA7 Biologics Sequence Review Report 2026: Interferon alpha-7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNA7 Biologics Sequence Review Report 2026: Interferon alpha-7 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNL4 Biologics Sequence Review Report 2026: Interferon lambda-4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNL4 Biologics Sequence Review Report 2026: Interferon lambda-4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNL4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IFNA8 Biologics Sequence Review Report 2026: Interferon alpha-8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IFNA8 Biologics Sequence Review Report 2026: Interferon alpha-8 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFNA8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →